By cytogenetic analysis, structural and numerical aberrations of chromosomes 1, 7, 8, 10, 16, and Y~ were identified in about 25% of the prostate carcinomas (PCs) studied. However, this figure is probably an underestimation of the true extent of the aberrations. This is because of selective isolation and preferential in vitro growth of nonmalignant prostate epitheliumY The use of interphase cytogenetic techniques for characterization of uncultured PC material has been stimulated by these findings. Application of in situ hybridization with centromere-specific DNA probes to fixed sections of PC has shown numerical aberrations for chromosomes 1, 7, 8, 10, 12, 17, 18 , X, and y4~7 The finding of numerical aberrations in different chromosomes is not surprising because about 50% of the PCs have an aneuploid DNA content. 8 In the present study, the authors investigated numerical changes of chromosomes 1, 7, 8, 10, 18 , and Y using fluorescence in situ hybridization (FISH) with centromere-specific DNA probes on nuclear suspensions of fresh tissue samples from 11 benign prostatic hyperplasia (BPH) and 43 PC patients. Selection of this chromosome panel was based on evidence from the literature and previous studies 9-a2 that these chromosomes were possibly implicated in PC development or progression. Study of recurring patterns of specific chromosomal aberrations might provide new information about the genetic events involved in these processes.
By cytogenetic analysis, structural and numerical aberrations of chromosomes 1, 7, 8, 10, 16 , and Y~ were identified in about 25% of the prostate carcinomas (PCs) studied. However, this figure is probably an underestimation of the true extent of the aberrations. This is because of selective isolation and preferential in vitro growth of nonmalignant prostate epitheliumY The use of interphase cytogenetic techniques for characterization of uncultured PC material has been stimulated by these findings. Application of in situ hybridization with centromere-specific DNA probes to fixed sections of PC has shown numerical aberrations for chromosomes 1, 7, 8, 10, 12, 17, 18 , X, and y4~7 The finding of numerical aberrations in different chromosomes is not surprising because about 50% of the PCs have an aneuploid DNA content. 8 In the present study, the authors investigated numerical changes of chromosomes 1, 7, 8, 10, 18 , and Y using fluorescence in situ hybridization (FISH) with centromere-specific DNA probes on nuclear suspensions of fresh tissue samples from 11 benign prostatic hyperplasia (BPH) and 43 PC patients. Selection of this chromosome panel was based on evidence from the literature and previous studies 9-a2 that these chromosomes were possibly implicated in PC development or progression. Study of recurring patterns of specific chromosomal aberrations might provide new information about the genetic events involved in these processes.
The BPH specimens showed no deviation from normal diploidy, so consequently the BPH results were used as a control. Based on this, significant chromosome gains and losses in the PC samples could be analyzed. Possible correlations with clinical parameters and ploidy as determined by DNA flow cytometry (FCM) were investigated.
MATERIALS AND METHODS

Tumor Tissues
Eleven BPH specimens were studied, after being obtained at transurethral resection (TUR) or prostatectomy for BPH. The mean age of the BPH patients was 72.4 _+ 5.6 (range, 64 to 80 years). Forty-six PC specimens, from 43 different patients were studied, obtained, and studied at radical prostatectomy (15 specimens), TUR (26 specimens), or pelvic lymph node dissection (five specimens). From one lymph node specimen (PC295), a cell line emerged after xenografting on nude mice. Tissue from this cell line at mouse passage was used instead of the original tissue. The mean age of the PC patients was 66.7 + 10.5 (range, 49 to 93 years). The percentage of tumor cells present in the tissue specimens was assessed from paraffin sections of adjacent tissue. Only specimens with more than 50% tumor cells were included in the study.
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720
Tissue Processing and Sample Preparation
Suspected benign hyperplasia or carcinoma tissues were excised and cut into several smaller fragments, snap frozen in liquid nitrogen, and stored at -80°C. For isolation of cells from tissue, approximately 0.5 mL of phosphate-buffered saline (PBS) was added to a thawed specimen. Subsequently, the tissue pieces were minced with a scalpel into a suspension of small cell clumps and single cells. The clumps were discarded after sedimentation for 3 to 5 minutes in 5 mL of PBS. The supernatant was centrifuged, and the resulting pellet washed and resuspended in PBS. The cell suspension was incubated with hypotonic solution (0.075 mol/L potassium chloride) for 10 minutes at 37°C and fixed in methanol/ acetic acid (3:1). Fixed cells were stored in methanol at -20°C until used for FISH. The previously described procedure was adequate for tissue processing, and fixation of nuclei from both primary tumor tissue and lymph node metastases. As nuclei from TUR tissue tended to coagulate in suspension, an additional sedimentation step at unit gravity was necessary for these preparations.
FCM Procedure
Samples were processed for DNA-FCM as described. 3 The ploidy of the different peaks in histograms from tumor samples was calculated from their position, relative to the GO/ G1 peak (C = 2) in a histogram of cultured normal diploid prostate fibroblasts. Diploid: C = 1.9 to 2.2; hypodiploid C 1.8; hyperdiploid C = 2.3 to 2.7; triploid: C = 2.8 to 3.4; tetraploid: C = 3.5 to 4.2. Samples had a significant tetraploid cell population when the tetraploid peak, representing diploid G2/M as well as tetraploid tumor G0/G1 nuclei, contained more than 10% of the nuclei.
FISH Procedure
The chromosome-specific probes used were PUC 1.77 for chromosome 114; p7t.1 for chromosome 715; D8Z2 for chromosome 816; D10Z1 for chromosome 1017; L1.84 for chromosome 1818; and DYZ5 (Amprobe; Amersham, Buckinghamshire, England) for the Y chromosome. Hybridization and detection were performed as described before. 2 Hybridization of the biotinylated probe (15 ng per slide) to the nuclei occurred during overnight incubation at 37°C in a moist chamber in 65% formamide for chromosomes 1, 18, and Y and in 60% formamide for chromosomes 7, 8, and 10.
Evaluation and Statistics
For the evaluation of FISH signals, the authors used the criteria defined by Hopman et a119: (1) nuclei should be intact and should not overlap; and (2) FISH signals within one nucleus should be completely separated (split or paired spots should be counted as one) and of the same intensity. When these criteria could not be met, such nuclei were excluded from counting. When more than 10% of the nuclei on a slide had to be excluded, the hybridization was repeated. When there were more than 5% nuclei with one spot on a slide, the hybridization was also repeated. At least 300 nuclei were scored per sample and per probe.
In mixed tumor-normal samples, small aberrations will not be detectable when the percentage of nontumor cells is too large. To compensate for this heterogeneity, only tumor samples that contained more than 50% tumor cells were electable for this study. So, depending on the cutoff percentage (range, 5% to 9%; Table 2 ), aberrations occurring in as few as 10% of the tumor cells could still be detected.
For each chromosome in each specimen, the average number of copies (ANC) was calculated (total number of spots counted/total number of nuclei counted). Consequently, an ANC of 0.90 for Ymeans that 10% of the nuclei in a tissue sample show no signal; an ANC of 2.15 means that a maximum of 15% of the nuclei show gain of one or more signals. The Kruskal-Wallis test was used to test the relation between the ANC and clinical stage, u scored with low frequency. Only the Y chromosome showed a relatively high mean (4.4%) for extra spots scored. Because no evidence for numerical abnormalities of the investigated chromosomes was shown, BPH could be considered a diploid control. Thus, the BPH results were used to assess cutoff ANCs (Table 2) . Significant gain and loss (further referred to as gain and loss) of the investigated chromosomes in PC are defined as at or above cutoffANC for gain and at or below cutoff ANC for loss, respectively.
PC Specimens
Detailed data per specimen and per chromosome are listed in Appendix 1. Significant numerical aberrations were detected for all six investigated chromosomes. Gain (trisomy and tetrasomy combined; occasionally, pentasomy and hexasomy) was more common than loss (monosomy and nullisomy). Gain was highest for chromosome 10 (64.7%) and lowest for chromosome Y (16.3%). Loss was highest for Y chromosome (14%) and lowest for chromosome 7 (2.6%). In metastatic tumors, more aberrations were detected than in nonmetastatic tumors. Five tumors did not show any abnormalities, whereas in 21 tumors one or more chromosomes showed simultaneous gain and loss. This resulted mostly in normal values for the ANC. 
RESULTS
BPH Specimens
For the 11 BPH specimens investigated, the ANCs for each investigated chromosome were narrowly distributed around the diploid values ( Loss of signals as well as extra spots were generally
The results for chromosome 1 showed gain in 37.8% but loss in less than 10% of the tumors (Fig 1) . Two cases (PC202 and PC302) showed simultaneous loss and gain. In metastatic tumors, gain was more frequent than in nonmetastatic tumors. Loss was found only in two metastatic tumors (PC295 and PC420). Polysomy was observed in all stage groups irrespective of long or short survival time of the patient (Table  1) . Statistics did not show any correlation of numerical aberrations with increasing stage, metastatic disease, or tumor site (Table 3) . 
Chromosome 7
Numerical aberrations of chromosome 7 were observed in 41% of the tumors. Although only one tumor (PC320) showed loss, gain was observed in 38.8% of the tumors. Seven tumors showed simultaneous loss and gain. Gain of chromosome 7 was more frequent in metastatic tumors, and a significant difference between the ANCs of nonmetastatic and metastatic tumors was found (Fig 1) . However, high percentages of polysomy were observed in two patients that were disease free for more than 2 years (PC290 and PC342; Table 1 ). The ANCs of radical prostatectomy specimens and lymph node metastasis (LM) specimens were significantly different (Table 3) .
Chromosome 8
The copy number of chromosome 8 was shown to be aberrant in 51% of the tumors. Gain of chromosome 8 was more frequently found in metastatic tumors, whereas loss occurred more often in nonmetastatic tumors (Fig 1) . Seven of 10 tumors with loss also showed gain. Four of five LM showed high percentages of polysomy (PC244, PC269, PC270, and PC295; Table 1 ). All these patients died within 2 years. However, also in one specimen from a patient who was disease free for more than 2 years (PC342), a high percentage of polysomy was found. High percentages of monosomy were observed in two lymph node-positive T3 tumors (PC256 and PC352). Significant differences in ANC values were found between nonmetastafic and metastatic tumors (Fig 1) , between radical prostatectomy and TUR specimens, and between radical prostatectomy and LM specimens (Table 3) .
Chromosome 10
Gain of chromosome 10, the most frequently found numerical aberration (64.7% of the tumors) cotrelated with metastatic disease (Fig 1) . Significant loss of chromosome 10 occurred in only one metastatic tumor (PC479). However, concurrent loss and gain of chromosome 10 was found in another 10 tumors. ANC values tended to increase with stage (P = .05) but showed no relation to the survival time. The ANCs of LM were significantly higher than those of radical prostatectomy specimens but were not different from TUR values (Table 3) .
Chromosome 18
Gain and loss of chromosome 18 were about equally frequent in nonmetastatic and in metastatic tumors (Fig 1) . High polysomy percentages were present in all stage groups, the highest values being found in patients with short survival (eg, PC269, PC270, and PC291; Table 1 ). Statistics did not reveal any correlation of numerical aberrations with tumor site (Table 3) .
Y Chromosome
Aberrations of Y chromosome, equally divided between loss and gain, did not correlate with any clinical parameter (Table 3) , although the frequency of loss was higher in metastatic tumors (Fig 1) . Only two cases showed simultaneous loss and gain (PC290 and PC332). 
DNA-FCM Compared With FISH Results of PC Patients With Follow-Up and Staging Data
Of the 24 specimens, investigated both by FISH analysis and DNA-FCM, seven tumors were DNA diploid, three were tetraploid, and 14 were aneuploid (Table 1). Six of seven DNA diploid tumors occurred in node-negative patients, whereas the three tetraploid tumors were all from node-positive patients. Aneuploid 
Cases With Multiple Specimens
PC256 and PC384 (case no. 4) showed a DNA histogram with about the same percentage of tetraploid cells (Fig 2) . FISH showed numerical aberrations for all investigated chromosomes in both specimens, but loss of chromosome 7 and gain of chromosome 10 were more pronounced in the second sample PC384.
The two samples obtained from case no. 5 (PC269 and PC291) displayed a profound dissimilarity in FCM results, with different proportions of different DNA content (Fig 2) . With FISH, all investigated chromosomes showed numerical aberrations in both samples. Although polysomy of chromosomes 1, 8, and especially 18 was far more extended in PC291, in PC269 chromosome 10 was more polysomic than in the second sample.
The two samples obtained from case no. 10 were also heterogeneous with respect to FCM results. In the TUR (PC320, sample contained 80% tumor cells), a triploid stemline (3.0C) was found, whereas in a sample from the xenografted cell line (PC295), which consequently consisted exclusively of tumor cells, a hypotetraploid (3.7C) and a hypodiploid stemline (1.4C) were observed (Fig 2) . The histograms of the FISH results showed, however, that these tumors were clearly related: Both samples showed polysomy for chromosomes 8 and 10, and loss for more than one chromosome. Losses were more extensive in PC295 than in PC320, except for Y chromosome, which was completely lost in PC320 and only partly lost in PC295.
DISCUSSION
In the BPH samples tested, essentially no numerical aberrations were detected for the six chromosomes investigated. These results are in contrast with the report of Aly et al, 2° who found loss of chromosome Y and gain of chromosome 7 in several cultured BPH specimens. Based on the findings in the present study, the authors assumed that occasional BPH cells would not Contribute to any chromosomal abnormalities found in PC specimens.
DNA-FCM studies on about one half of the tumors showed that the frequency of DNA aneuploidy increased with increasing tumor stage. Combined FISH and DNA-FCM showed that, as expected, most aneuploid tumors had numerical chromosomal aberrations. It was, however, also shown that most diploid tumors also had one or more numerically aberrant chromosomes. This can be explained by the fact that only chromosomal aberrations that constitute more than 4% of the total amount of DNA can be detected with DNA-FCM. No chromosome seemed to be specifically aberrant in DNA diploid tumors.
Forty-one of 46 PCs showed numerical aberrations of one or more chromosomes of the six chromosome panel. All investigated chromosomes individually showed numerical aberrations in at least 30% of the specimens, and gain was more frequent than loss. Gain of chromosome 10 was the most frequent numerical aberration found (65%); chromosome 8 was the second most frequently gained chromosome (44%); and chromosomes 1, 7, and 18 showed gain with a frequency between 35% and 40%. The Y chromosome showed the lowest frequency of gain (16%), but the highest frequency of loss (14%). Gain of chromosomes 7, 8, and 10 correlated with metastatic disease. Moreover, the ANC of chromosome 10 was significantly higher in advanced tumors. Gain of chromosome 10 in PC has been reported before, l° and deletions of part of 10q have been reported in cytogenetic ~'21 and loss ofhetero- 10 22~24 zygosity (LOH) studies. ' " However, the association of chromosome 10 aberrations with metastatic disease is a new finding.
In a previous study, the authors of the present study were the first to suggest that 8p deletions are possibly important aberrations in PC. 25 Since then, 8p deletions have been reported in several cytogenetic studies of PCs. 1 '10'26-28 Recently, the importance of loss of chromosome 8p sequences in PC and the putative presence of at least two tumor suppressor genes on chromosome 8p has been established by several LOH studies. 26-31 The deletions that were found by LOH mapping often spanned most of the 8p arm and sometimes involved the centromerle region. In the present study, loss of chromosome 8 was seen primarily in nonmetastatic tumors, whereas in metastatic tumors gain was more prominent.
Deletions of 7q are among the first aberrations reported in PC. ~ Gain of chromosome 7 has been found in cytogenetic 5' 21' 22"a2 and FISH studies. 1° '11'33'34 In agreement with the findings in the present study, Bandyk et a111 observed that gain of chromosome 7 was significantly increased in PC metastases compared with primary tumors.
Loss of chromosomes 7, 8, and 10 was observed mostly simultaneously with gain in the same tumor samples, which is suggestive for heterogeneity in such tumors. In fact, chromosome 8 centromere gains and losses were shown to exist in different areas of the same tumors. 5 Loss of (part of) a homologue followed by multiplication of the other homologue is one possible mechanism through which these numerical aberrations could be generated. Another mechanism could be the formation of an isochromosome, followed by a nondisjunction event. This has been suggested as an explana- tion for the simultaneous loss of 8p and gain of 8q. 27
In a recent comparative genome hybridization study of PC, it was reported that loss of 8p and gain of 8q occur frequently, but that gain of (the whole) 7 and loss of 10q are infrequent observations. 35 Chromosome 18 likewise showed simultaneous loss and gain in most tumors, suggesting similar possible mechanisms as stated previously. The percentage of numerical aberrations of chromosome 18, however, did not correlate with metastatic disease. Moreover, the authors have reported before that DNA diploid PCs, which mostly are early] tumors, often already show gain of 2 chromosome 18. " So numerical aberrations of chromosome 18 are likely to be an early event in PC. In fact, recently allelic losses of 18q were reported in six of 20 early-stage PCs. ~6 It will be of interest to investigate if chromosome 18 aberrations are already present in the preneoplastic prostatic intraepithelial neoplasia lesions.
Aberrations of both chromosomes 1 and Y also did not correlate with metastatic disease. Furthermore, simultaneous loss and gain were only rarely observed. Previously, the authors 2 described that gain of chromosomes 1 and Ywas largely restricted to DNA aneuploid tumors, and this finding was confirmed in the present study. Y loss in the tumor did not correlate with the patients age. So alternative mechanisms, like multiplication through tetraploidization of the whole genome 37 or loss of Yas a reflection of a general state of hyperproliferation, 3s are more likely explanations for the aberrations found for these chromosomes.
Comparison of two consecutive samples from the same patients revealed similar results with FCM in only one of three cases. However, FISH analysis of these specimens revealed clear evidence of karyotypic evolution toward a more aberrant karyotype.
The present article has substantiated the value of centromere FISH as a means to look at the ploidy of individual chromosomes in prostate cancer tissue. Numerical aberrations were found for all six investigated chromosomes; no doubt, most other chromosomes, when eventually investigated, will also show numerical aberrations in at least part of the PCs. The most important finding was, however, that combined with clinical data, gains of chromosomes 7, 8, and 10 were shown to be definitely involved in the progression of PC. This not only substantiates the postulated presence of tumor suppressor genes on 8p but also justifies renewed interest in the commonly deleted regions on 7q and 10% 1 
